Johnson & Johnson (JNJ) Stock Analysis
Is JNJ a good investment?
Johnson & Johnson (JNJ) has a Plutrex AI rating of 61.0/100 as of August 21, 2026, indicating a Hold consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Fortress balance sheet: D/E of 0.44 (75.3% below industry average of 1.778), $20.76B cash, and $16.89B annual FCF — enabling simultaneous dividends, buybacks, M&A, and talc litigation absorption without financial stress; net margin of 21.48% is 44.8% above the industry average of 14.83%. Main concern: Valuation remains stretched and has WORSENED: PEG of 2.16 (up from 2.12 prior report, 22.8% premium to industry average of 1.759), P/E of 30.99x (up from 30.38x) for a company with -0.9% historical earnings growth, and analyst consensus target of $277.81 implying only 3.9% upside — stock has risen $5.29 (+2.0%) since prior report, moving further from the $245-$255 entry zone; headline 'Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now' directly validates this concern.
Investment Summary
Johnson & Johnson (JNJ) at $267.37 is a world-class business trading at a stretched valuation that offers minimal margin of safety for new buyers. The core tension: exceptional profitability (net margin 21.48% vs. industry 14.83%, ROE 25.7%, FCF $16.89B annually) collides with a PEG ratio of 2.16 — 22.8% above the industry average of 1.759 — and an analyst consensus target of $277.81 implying only 3.9% upside from current price. The stock has risen another 2.0% from $262.08 to $267.37 since the prior report, moving further from the $245-$255 entry zone. Historical earnings growth of -0.9% YoY directly contradicts the forward 10% EPS growth projection. News sentiment is constructive (89.3/100, 8 positive articles) — pipeline drugs Icotyde, Inlexzo, and Rybrevant are positioned to offset Stelara patent cliff losses, and 64 consecutive years of dividend increases confirm durable cash generation — but positive news does not resolve the valuation math. For existing holders, JNJ remains a core dividend compounder. For new buyers, the stock is now $12.37 above the upper bound of the prior entry zone, making patience the correct posture.
Key Strengths
- Fortress balance sheet: D/E of 0.44 (75.3% below industry average of 1.778), $20.76B cash, and $16.89B annual FCF — enabling simultaneous dividends, buybacks, M&A, and talc litigation absorption without financial stress; net margin of 21.48% is 44.8% above the industry average of 14.83%
- 64 consecutive years of dividend increases (Dividend King status) backed by $16.89B annual FCF — confirmed by news coverage as '5 Dividend Aristocrats to Buy for Lifelong Income' and '5 Dependable Dividend Stocks to Buy in August'; pipeline drugs Icotyde, Inlexzo, and Rybrevant provide credible Stelara offset narrative per 'J&J's New Growth Powerhouses: Immunology and Neuroscience'
- 5-year forward EPS growth of 9.72% beats the industry average of 8.16% by 19.1% — superior long-term compounding profile vs. peers, with ROE of 25.7% achieved through genuine business quality rather than financial leverage (D/E only 0.44)
Key Concerns
- Valuation remains stretched and has WORSENED: PEG of 2.16 (up from 2.12 prior report, 22.8% premium to industry average of 1.759), P/E of 30.99x (up from 30.38x) for a company with -0.9% historical earnings growth, and analyst consensus target of $277.81 implying only 3.9% upside — stock has risen $5.29 (+2.0%) since prior report, moving further from the $245-$255 entry zone; headline 'Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now' directly validates this concern
- Critical growth deficit vs. peers is UNCHANGED: historical earnings growth of -0.9% vs. industry average +18.49% (a 19.4 percentage point gap), forward 1-year EPS growth of 10.04% vs. industry average 154.35%, and Stelara patent cliff represents a significant near-term revenue headwind that new pipeline drugs must overcome — ongoing litigation remains a persistent risk factor per news analysis
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Profitability is elite: gross margin 68.0% (vs. industry 68.94%, essentially at parity), operating margin 29.19% (vs. industry 29.98%, near parity), net margin 21.48% (44.8% ABOVE industry average of 14.83%), and ROE of 25.7% achieved with conservative D/E of only 0.44 (75.3% BELOW industry average of 1.778). FCF of $16.89B and cash of $20.76B create a fortress balance sheet. Growth is the critical weakness: historical earnings growth of -0.9% YoY vs. industry average +18.49% — JNJ is the only major peer with negative trailing earnings growth. Forward 1-year EPS growth of 10.04% vs. industry average 154.35% (even adjusting for outlier distortion, JNJ is clearly bottom-tier on near-term growth). The one growth bright spot: 5-year forward EPS growth of 9.72% beats the industry average of 8.16% by 19.1%, confirming JNJ's long-term compounding story is above-average. Valuation: P/E of 30.99x is 9.1% below the industry average of 34.10x (modest relative advantage), but PEG of 2.16 is 22.8% ABOVE the industry average of 1.759 — investors pay more per unit of growth for JNJ than for the average peer despite JNJ's inferior near-term growth. Analyst consensus target of $277.81 implies only 3.9% upside. Price-to-Book of 7.58 leaves minimal asset-based downside protection. The fundamental picture is: exceptional quality, poor value at current price.
News Sentiment
Johnson & Johnson continues to generate mostly positive headlines, but the underlying story is one of a blue-chip giant navigating a critical transition period. The company's 64-year streak of consecutive dividend increases — highlighted in both '5 Dividend Aristocrats to Buy for Lifelong Income in August' and '5 Dependable Dividend Stocks to Buy in August' — remains the cornerstone of its investment appeal, signaling to income investors that management's commitment to shareholder returns is ironclad. Behind the scenes, however, J&J is fighting a battle against the clock. The blockbuster drug Stelara is losing patent protection, and the company is racing to fill that revenue gap with three newer drugs: Icotyde, Inlexzo, and Rybrevant — a story detailed in 'J&J's New Growth Powerhouses: Immunology and Neuroscience.' Early signs are encouraging, but the transition is not without risk. Meanwhile, ongoing litigation remains a persistent overhang, and even some bullish analysts are pumping the brakes on valuation. The headline 'Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now' captures the market's dilemma perfectly — this is an exceptional company, but the stock price may already reflect that excellence. For everyday investors, the message is simple: J&J is a reliable dividend machine with a solid pipeline, but buying at today's price means paying a premium for quality with limited near-term upside.
Risk Assessment
PRIMARY RISK: Valuation compression. At PEG 2.16 and P/E 30.99x with only 3.9% analyst upside, any earnings disappointment or guidance cut could trigger a 10-15% de-rating. The Stelara patent cliff is the most concrete near-term revenue risk — biosimilar competition is accelerating and new pipeline drugs (Icotyde, Inlexzo, Rybrevant) must ramp quickly to offset losses. SECONDARY RISK: Ongoing talc litigation — while JNJ's $20.76B cash fortress can absorb settlements, headline risk and potential large adverse judgments remain unpredictable. TERTIARY RISK: Historical earnings growth of -0.9% makes the forward 10% EPS growth projection aspirational; if analysts revise down, the stock's premium multiple becomes even harder to justify. MITIGATION: JNJ's $16.89B annual FCF, 64-year dividend streak, and D/E of 0.44 provide substantial downside cushion. Stop loss at $235 (6% below $250 entry midpoint) limits downside. Position sizing at 3.0% reflects quality but acknowledges valuation risk.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is JNJ a halal stock?
Yes, Johnson & Johnson (JNJ) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for JNJ?
Johnson & Johnson (JNJ) has a Plutrex AI rating of 61.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is JNJ a good investment?
According to Plutrex AI, JNJ has a Hold rating (61.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in JNJ?
US stocks like JNJ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in JNJ?
Plutrex AI identifies the main risks for JNJ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.